|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He J, Gu D, Wu X, Reynolds K, Duan X, Yao
C, Wang J, Chen CS, Chen J, Wildman RP, et al: Major causes of
death among men and women in China. N Engl J Med. 353:1124–1134.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Livraghi T, Makisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011.PubMed/NCBI
|
|
4
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malan-Müller S, Hemmings SM and Seedat S:
Big effects of small RNAs: A review of microRNAs in anxiety. Mol
Neurobiol. 47:726–739. 2013. View Article : Google Scholar :
|
|
7
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar :
|
|
11
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li G, Shen Q, Li C, Li D, Chen J and He M:
Identification of circulating microRNAs as novel potential
biomarkers for hepatocellular carcinoma detection: A systematic
review and meta-analysis. Clin Transl Oncol. 7:684–693. 2015.
View Article : Google Scholar
|
|
13
|
Saito Y, Suzuki H, Matsuura M, Sato A,
Kasai Y, Yamada K, Saito H and Hibi T: MicroRNAs in hepatobiliary
and pancreatic cancers. Front Genet. 2:662011. View Article : Google Scholar
|
|
14
|
Lin SP, Youngson N, Takada S, Seitz H,
Reik W, Paulsen M, Cavaille J and Ferguson-Smith AC: Asymmetric
regulation of imprinting on the maternal and paternal chromosomes
at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat
Genet. 35:97–102. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang W, Peng B, Wang D, Ma X, Jiang D,
Zhao J and Yu L: Human tumor microRNA signatures derived from
large-scale oligonucleotide microarray datasets. Int J Cancer.
129:1624–1634. 2011. View Article : Google Scholar
|
|
16
|
Miranda PJ, Vimalraj S and Selvamurugan N:
A feedback expression of microRNA-590 and activating transcription
factor-3 in human breast cancer cells. Int J Biol Macromol.
72:145–150. 2015. View Article : Google Scholar
|
|
17
|
Lin X, Yang Z, Zhang P and Shao G: miR-154
suppresses non-small cell lung cancer growth in vitro and in vivo.
Oncol Rep. 33:3053–3060. 2015.PubMed/NCBI
|
|
18
|
Xin C, Zhang H and Liu Z: miR-154
suppresses colorectal cancer cell growth and motility by targeting
TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar
|
|
19
|
Mian C, Pennelli G, Fassan M, Balistreri
M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo
MR, et al: MicroRNA profiles in familial and sporadic medullary
thyroid carcinoma: Preliminary relationships with RET status and
outcome. Thyroid. 22:890–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q,
An J, Dong X, Liu F and Wang Y: ZEB2 promotes vasculogenic mimicry
by TGF-β1 induced epithelial-to-mesenchymal transition in
hepatocellular carcinoma. Exp Mol Pathol. 98:352–359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu K, Liu S, Zhang W, Ji B, Wang Y and
Liu Y: miR-222 regulates sorafenib resistance and enhance
tumorigenicity in hepatocellular carcinoma. Int J Oncol.
45:1537–1546. 2014.PubMed/NCBI
|
|
22
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010.
2015.PubMed/NCBI
|
|
23
|
Chai ZT, Zhu XD, Ao JY, Wang WQ, Gao DM,
Kong J, Zhang N, Zhang YY, Ye BG, Ma DN, et al: microRNA-26a
suppresses recruitment of macrophages by down-regulating macrophage
colony-stimulating factor expression through the PI3K/Akt pathway
in hepatocellular carcinoma. J Hematol Oncol. 8:562015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang G, Cui Y, Yu X, Wu Z, Ding G and Cao
L: miR-211 suppresses hepatocellular carcinoma by downregulating
SATB2. Oncotarget. 6:9457–9466. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verschueren K, Remacle JE, Collart C,
Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT,
Bodmer R, et al: SIP1, a novel zinc finger/homeodomain repressor,
interacts with Smad proteins and binds to 5′-CACCT sequences in
candidate target genes. J Biol Chem. 274:20489–20498. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB,
Hou JH and Yun JP: Overexpression of ZEB2 in peritumoral liver
tissue correlates with favorable survival after curative resection
of hepatocellular carcinoma. PLoS One. 7:e328382012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vandewalle C, Comijn J, De Craene B,
Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and
Berx G: SIP1/ZEB2 induces EMT by repressing genes of different
epithelial cell-cell junctions. Nucleic Acids Res. 33:6566–6578.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p
inhibits epithelial-mesenchymal transition, migration and invasion
of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao
Y, Ma B, Wang X, Wu N, Li X, et al: MicroRNA-200a suppresses
metastatic potential of side population cells in human
hepatocellular carcinoma by decreasing ZEB2. Oncotarget.
6:7918–7929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu SM, Ai HW, Zhang DY, Han XQ, Pan Q, Luo
FL and Zhang XL: miR-141 targets ZEB2 to suppress HCC progression.
Tumour Biol. 35:9993–9997. 2014. View Article : Google Scholar : PubMed/NCBI
|
